Your browser doesn't support javascript.
loading
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Craddock, Charles; Jackson, Aimee; Loke, Justin; Siddique, Shamyla; Hodgkinson, Andrea; Mason, John; Andrew, Georgia; Nagra, Sandeep; Malladi, Ram; Peniket, Andrew; Gilleece, Maria; Salim, Rahuman; Tholouli, Eleni; Potter, Victoria; Crawley, Charles; Wheatley, Keith; Protheroe, Rachel; Vyas, Paresh; Hunter, Ann; Parker, Anne; Wilson, Keith; Pavlu, Jiri; Byrne, Jenny; Dillon, Richard; Khan, Naeem; McCarthy, Nicholas; Freeman, Sylvie D.
Afiliación
  • Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Jackson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Loke J; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Siddique S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Hodgkinson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Mason J; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Andrew G; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Nagra S; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
  • Malladi R; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • Peniket A; Addenbrookes Hospital, Cambridge, United Kingdom.
  • Gilleece M; Churchill Hospital, Oxford, United Kingdom.
  • Salim R; St James's Hospital, Leeds, United Kingdom.
  • Tholouli E; Royal Liverpool University Hospital, United Kingdom.
  • Potter V; Manchester Royal Infirmary, Manchester, United Kingdom.
  • Crawley C; Kings College Hospital, London, United Kingdom.
  • Wheatley K; Addenbrookes Hospital, Cambridge, United Kingdom.
  • Protheroe R; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
  • Vyas P; Bristol Haematology and Oncology Centre, United Kingdom.
  • Hunter A; Churchill Hospital, Oxford, United Kingdom.
  • Parker A; Leicester Royal Infirmary, United Kingdom.
  • Wilson K; Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Pavlu J; University Hospital Wales, United Kingdom.
  • Byrne J; Imperial College Hospital, London, Unite Kingdom.
  • Dillon R; Centre for Clinical Haematology, Nottingham, United Kingdom.
  • Khan N; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
  • McCarthy N; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
  • Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
J Clin Oncol ; 39(7): 768-778, 2021 03 01.
Article en En | MEDLINE | ID: mdl-33373276

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vidarabina / Síndromes Mielodisplásicos / Amsacrina / Busulfano / Leucemia Mieloide Aguda / Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Citarabina / Trasplante de Células Madre / Inmunosupresores Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vidarabina / Síndromes Mielodisplásicos / Amsacrina / Busulfano / Leucemia Mieloide Aguda / Acondicionamiento Pretrasplante / Agonistas Mieloablativos / Citarabina / Trasplante de Células Madre / Inmunosupresores Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Clin Oncol Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido